Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP02726984A		Genentech, Inc.	Patent maintained as amended
EP17710160A	2022-05-04	STADA Arzneimittel AG	Granted and Under Opposition
EP17710160A	2022-05-04	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP17710160A	2022-05-03	SANDOZ AG	Granted and Under Opposition
EP17710160A	2022-05-03	Adalvo Ltd.	Granted and Under Opposition
EP17710160A	2022-04-28	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP17196501A	2019-12-06	Hoffmann Eitle	Granted and Under Opposition
EP17196501A	2019-12-06	Generics (U.K.) Limited	Granted and Under Opposition
EP17196501A	2019-12-05	Dr. Reddy's Laboratories Limited	Granted and Under Opposition
EP17196501A	2019-12-04	Galenicum Health S.L.U.	Granted and Under Opposition
EP17196501A	2019-12-04	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP04797453A	2018-08-22	Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB	Opposition rejected
EP04797453A	2018-08-21	Wittkopp, Alexander	Opposition rejected
EP04797453A	2018-08-21	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP04797453A	2018-08-21	Generics (U.K.) Limited	Opposition rejected
EP04797453A	2018-08-20	Sandoz AG	Opposition rejected
EP04797453A	2018-08-20	Fresenius Kabi Deutschland GmbH	Opposition rejected
EP06701034A	2018-01-19	Schwöbel, Thilo	Opposition rejected
EP06754730A	2011-12-02	Ypsomed AG	Patent maintained as amended
EP06754730A	2011-11-30	WMC Matthes Consulting	Patent maintained as amended
EP06762643A	2010-07-30	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP05796880A	2010-07-14	Ypsomed AG	Granted and Under Opposition
EP05796880A	2010-07-14	Stöckeler, Ferdinand	Granted and Under Opposition
EP05796880A	2010-07-13	Ferring International Center S.A.	Granted and Under Opposition
EP05796880A	2010-07-13	OWEN MUMFORD LIMITED	Granted and Under Opposition
EP05796880A	2010-07-12	Genentech, Inc.	Granted and Under Opposition
EP05796880A	2010-07-12	COPERNICUS sp. zo.o.	Granted and Under Opposition
EP06121820A	2010-05-18	SANOFI-AVENTIS DEUTSCHLAND GMBH	Opposition rejected
EP02745182A	2008-09-26	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected
EP02726984A	2006-03-01	TecPharma Licensing AG	Patent maintained as amended
EP02726984A	2006-02-23	OWEN MUMFORD LIMITED	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8114833	March, 2022	Terminated-Settled	Novo Nordisk A/S	Fresenius Kabi USA, LLC
US8114833	July, 2020	Terminated-Settled	Novo Nordisk A/S	Pfizer Inc.
US8114833	December, 2019	Terminated-Settled	Novo Nordisk A/S et al.	Pfizer Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7235627	NOVO	Derivatives of GLP-1 analogs	Aug, 2017 (6 years ago)
US6458924	NOVO	Derivatives of GLP-1 analogs	Aug, 2017 (6 years ago)
US6268343	NOVO	Derivatives of GLP-1 analogs	Aug, 2022 (1 year, 8 months ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699	NOVO	Automatic injection device with reset feature	Jan, 2022 (2 years ago)
US8672898	NOVO	Automatic injection device with reset feature	Jan, 2022 (2 years ago)
US9486588	NOVO	Automatic injection device with reset feature	Jan, 2022 (2 years ago)
US8846618	NOVO	Stable formulation of modified GLP-1	Jun, 2022 (1 year, 9 months ago)
US6899699 (Pediatric)	NOVO	Automatic injection device with reset feature	Jul, 2022 (1 year, 9 months ago)
US8672898 (Pediatric)	NOVO	Automatic injection device with reset feature	Jul, 2022 (1 year, 9 months ago)
US9486588 (Pediatric)	NOVO	Automatic injection device with reset feature	Jul, 2022 (1 year, 9 months ago)
US8846618 (Pediatric)	NOVO	Stable formulation of modified GLP-1	Dec, 2022 (1 year, 3 months ago)
US6268343 (Pediatric)	NOVO	Derivatives of GLP-1 analogs	Feb, 2023 (1 year, 2 months ago)
US8579869	NOVO	Needle mounting system and a method for mounting a needle assembly	Jun, 2023 (9 months ago)
US8579869 (Pediatric)	NOVO	Needle mounting system and a method for mounting a needle assembly	Dec, 2023 (3 months ago)
US7762994	NOVO	Needle mounting system and a method for mounting a needle assembly	May, 2024 (29 days from now)
US7762994 (Pediatric)	NOVO	Needle mounting system and a method for mounting a needle assembly	Nov, 2024 (6 months from now)
US8114833	NOVO	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Aug, 2025 (1 year, 3 months from now)
US8684969	NOVO	Injection device with torsion spring and rotatable display	Oct, 2025 (1 year, 5 months from now)
US11446443	NOVO	Injection device with torsion spring and rotatable display	Oct, 2025 (1 year, 5 months from now)
US10357616	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (1 year, 8 months from now)
US9616180	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (1 year, 8 months from now)
US11311679	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (1 year, 8 months from now)
US9861757	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (1 year, 8 months from now)
US10376652	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (1 year, 8 months from now)
US9108002	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (1 year, 9 months from now)
US8114833 (Pediatric)	NOVO	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Feb, 2026 (1 year, 9 months from now)
US8684969 (Pediatric)	NOVO	Injection device with torsion spring and rotatable display	Apr, 2026 (1 year, 11 months from now)
US9775953	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
US11097063	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jul, 2026 (2 years from now)
US8920383	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
US10220155	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jul, 2026 (2 years from now)
US9861757 (Pediatric)	NOVO	Injection device with an end of dose feedback mechanism	Jul, 2026 (2 years from now)
US9616180 (Pediatric)	NOVO	Automatic injection device with a top release mechanism	Jul, 2026 (2 years from now)
US9108002 (Pediatric)	NOVO	Automatic injection device with a top release mechanism	Jul, 2026 (2 years from now)
US7686786	NOVO	Dial-down mechanism for wind-up pen	Aug, 2026 (2 years from now)
USRE46363	NOVO	Dial-down mechanism for wind-up pen	Aug, 2026 (2 years from now)
US10220155 (Pediatric)	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jan, 2027 (2 years from now)
US8920383 (Pediatric)	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jan, 2027 (2 years from now)
US9775953 (Pediatric)	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jan, 2027 (2 years from now)
USRE46363 (Pediatric)	NOVO	Dial-down mechanism for wind-up pen	Feb, 2027 (2 years from now)
US9687611	NOVO	Injection device with torsion spring and rotatable display	Feb, 2027 (2 years from now)
US9687611 (Pediatric)	NOVO	Injection device with torsion spring and rotatable display	Aug, 2027 (3 years from now)
US9457154	NOVO	Injection device with an end of dose feedback mechanism	Sep, 2027 (3 years from now)
US9457154 (Pediatric)	NOVO	Injection device with an end of dose feedback mechanism	Mar, 2028 (3 years from now)
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (7 years from now)
US9132239 (Pediatric)	NOVO	Dial-down mechanism for wind-up pen	Aug, 2032 (8 years from now)
US9968659	NOVO	Liraglutide in cardiovascular conditions	Jan, 2037 (12 years from now)
US9968659 (Pediatric)	NOVO	Liraglutide in cardiovascular conditions	Jul, 2037 (13 years from now)

Saxenda is owned by Novo.

Saxenda contains Liraglutide Recombinant.

Saxenda has a total of 48 drug patents out of which 14 drug patents have expired.

Expired drug patents of Saxenda are:

US6899699
US8672898
US9486588
US8846618
US6899699*PED
US8672898*PED
US9486588*PED
US8846618*PED
US6268343*PED
US8579869
US8579869*PED
US7235627
US6458924
US6268343

Saxenda was authorised for market use on 23 December, 2014.

Saxenda is available in solution;subcutaneous dosage forms.

Saxenda can be used as cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease, method for chronic weight management by treating obesity.

Drug patent challenges can be filed against Saxenda from 25 January, 2014.

The generics of Saxenda are possible to be released after 09 July, 2037.

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 04, 2023
New Chemical Entity Exclusivity(NCE)	Jan 25, 2015
New Product(NP)	Jan 25, 2017

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

NCE-1 date:

25 January, 2014

Market Authorisation Date:

23 December, 2014

Treatment:

Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage:

SOLUTION;SUBCUTANEOUS

Pharsight

Saxenda patents expiration

SAXENDA's oppositions filed in EPO

SAXENDA Litigations

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

NCE-1 date:

Market Authorisation Date:

Treatment:

Dosage:

More Information on Dosage

SAXENDA family patents

Related content